Immunoassay of Antibody-Drug
Conjugates (ADCs)
—Pharmacokinetic (PK)
Characterization of ADCs
As
a leader in the development of antibody-drug conjugates (ADCs), Creative
Diagnostics has developed a portfolio of ELISA kits for the quantitative
detection of conjugate antibodies targeting commonly encountered payloads such
as MMAE, SN38 and DM1. These kits provide highly sensitive monitoring of
conjugate antibody concentrations in serum and plasma, with high
reproducibility and inter-batch consistency of test results. They are excellent
tools for PK studies of ADCs.
For
conjugated antibody quantification, the capture reagent is the antibody
targeting the cytotoxic drug. After capturing the conjugated antibody, the
amount is quantified using biotin antigen or anti-CDR mAb.
Fig.1 Principle of
Conjugated Antibody Quantitative Detection
Key Features:
● For PK assay of ADCs in pre-clinical/clinical studies (for research use
only)
● No cross-reactivity with other ADC analogs
● Lot-to-lot consistency
● High specificity/sensitivity/stability
● Passed stability test at 37°C for 7 days
Product
List
(주)엘바이오시스템은 Creative Diagnostics의 한국공식대리점입니다.